Peptides International Japan

CDMO

Japan

https://peptides.co.jp/

Is this your company? Claim this profile

Excipients & Specialty Ingredients

Regulatory, Tech Transfer & Support Services

Company Overview

About

Peptides International Japan is a pharmaceutical CDMO offering comprehensive services.

Key Expertise

Specialized in API Manufacturing, Sterile Fill/Finish, Lyophilization

Therapeutic Areas

Oncology

Hematology

Quick Facts

HQ:Japan

Founded:2003

Employees:2,991

Capabilities & Services

Core Capabilities

Oral Solid Dose
Solid Dose Manufacturing
Formulation Development

Types of Organization

GMP Manufacturing

Quality Systems

Regulatory Support

Dosage Forms

Lyophilized (Freeze-Dried)

Sterile Injectable

Containment Capabilities

OEB 5 (≤1 µg/m³)

Cytotoxic / ADC Handling

Production Scales

Commercial Scale

Large Scale (Metric Ton+)

Markets Served

Asia-Pacific

Regulatory Approvals

Drug Approval MGRYQA

EMA · #APR-LKCEVX6J · 2019-01-01

Drug Approval 84N4DZ

FDA · #APR-XJ1RK90A · 2020-12-01

Case Studies

0 published case studies showcasing past projects, challenges and outcomes.

Certifications

FDA Registration

U.S. Food and Drug Administration

Cert #: CERT-A3BP70RU

Issued: 2020-09-24

Expires: 2025-05-06

EMA GMP Certificate

European Medicines Agency

Cert #: CERT-UX5IPNGU

Issued: 2020-02-02

Expires: 2025-10-16

Loading CDMO intelligence...

Request an Introduction

Please log in to contact this provider.

Key facts about Peptides International Japan

Peptides International Japan is headquartered in Japan.
Peptides International Japan was founded in 2003.
Peptides International Japan has 2,991 employees.
Peptides International Japan's capabilities include Oral Solid Dose, Solid Dose Manufacturing and Formulation Development.

Find CDMOs like Peptides International Japan

Directory pages this company appears in, each with the full list of matching manufacturers.

CDMOs in Japan CDMOs in Asia Oral Solid Dose CDMOs Formulation Development CDMOs Lyophilized (Freeze-Dried) CDMOs Sterile Injectable CDMOs OEB 5 (≤1 µg/m³) CDMOs Cytotoxic / ADC Handling CDMOs